Evidence map›Paper›PMID 33664772›Full record

ReviewFrontiers in genetics2021

Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India.

Sreyashi Majumdar, Rohit Verma, Avishek Saha, Parthasarathi Bhattacharyya, Pradipta Maji, Milan Surjit, Manikuntala Kundu, Joyoti Basu, Sudipto Saha

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sreyashi MajumdarDivision of Bioinformatics, Bose Institute, Kolkata, India.
Rohit VermaVirology Laboratory, Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Avishek SahaUbiquitous Analytical Techniques, CSIR-Central Scientific Instruments Organisation, Chandigarh, India.
Parthasarathi BhattacharyyaDepartment of Respiratory Medicine, Institute of Pulmocare and Research, Kolkata, India.
Pradipta MajiBiomedical Imaging and Bioinformatics Lab, Machine Intelligence Unit, Indian Statistical Institute, Kolkata, India.
Milan SurjitVirology Laboratory, Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Manikuntala KunduDepartment of Chemistry, Bose Institute, Kolkata, India.
Joyoti BasuDepartment of Chemistry, Bose Institute, Kolkata, India.
Sudipto SahaDivision of Bioinformatics, Bose Institute, Kolkata, India.
Bose Institute · INTranslational Health Science and Technology Institute · INCentral Scientific Instruments Organisation · INIndian Statistical Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus induced disease-2019 (COVID-19), is a type of common cold virus responsible for a global pandemic which requires immediate measures for its containment. India has the world's largest population aged between 10 and 40 years. At the same time, India has a large number of individuals with diabetes, hypertension and kidney diseases, who are at a high risk of developing COVID-19. A vaccine against the SARS-CoV-2, may offer immediate protection from the causative agent of COVID-19, however, the protective memory may be short-lived. Even if vaccination is broadly successful in the world, India has a large and diverse population with over one-third being below the poverty line. Therefore, the success of a vaccine, even when one becomes available, is uncertain, making it necessary to focus on alternate approaches of tackling the disease. In this review, we discuss the differences in COVID-19 death/infection ratio between urban and rural India; and the probable role of the immune system, co-morbidities and associated nutritional status in dictating the death rate of COVID-19 patients in rural and urban India. Also, we focus on strategies for developing masks, vaccines, diagnostics and the role of drugs targeting host-virus protein-protein interactions in enhancing host immunity. We also discuss India's strengths including the resources of medicinal plants, good food habits and the role of information technology in combating COVID-19. We focus on the Government of India's measures and strategies for creating awareness in the containment of COVID-19 infection across the country.

Indexed as

artificial intelligenceCT scansgenetic variationshost immuno-modulationmedicinal plantsrepurposed drugsSARS-CoV-2vaccines

Identifiers

PMID33664772
PMCPMC7921795
OpenAlexW3131864320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.